Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial
- Resource Type
- Source
- Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, 2018, 73 (4), pp.1020-1024. ⟨10.1093/jac/dkx498⟩ - Subject
Male 0301 basic medicine MESH: Raltegravir Potassium [SDV]Life Sciences [q-bio] HIV Infections Pharmacology Maraviroc MESH: HIV-1 Plasma chemistry.chemical_compound Pharmacology (medical) MESH: Anti-HIV Agents MESH: Maraviroc Darunavir MESH: Darunavir education.field_of_study MESH: Middle Aged MESH: HIV Infections Middle Aged Viral Load Infectious Diseases MESH: Young Adult Female MESH: Viral Load Viral load medicine.drug Adult Microbiology (medical) Anti-HIV Agents 030106 microbiology Population Emtricitabine Young Adult 03 medical and health sciences Pharmacokinetics Raltegravir Potassium medicine Humans education MESH: Plasma Models, Statistical Ritonavir MESH: Humans business.industry MESH: Adult Raltegravir MESH: Male 030104 developmental biology chemistry HIV-1 MESH: Ritonavir business MESH: Female MESH: Models, Statistical - Language
- English
- ISSN
- 0305-7453
1460-2091